Skip to main content
Premium Trial:

Request an Annual Quote

Rheonix, Life Tech to Develop MDx Platform for Food Safety Testing

NEW YORK (GenomeWeb News) – Molecular diagnostics company Rheonix today announced a joint development agreement with Life Technologies aimed at a molecular testing platform for the applied markets.

Rheonix will supply its technology developed for the molecular diagnostics market, including its CARD disposable cartridges, to Life Tech for marketing, sales and distribution. Together the two companies will develop a platform designed for the food safety testing market that will enable laboratories to detect disease-causing organisms, including serotype identification in a fully automated format. The platform is targeted for a market launch next year.

The CARD system is a microfluidic platform that fully automates all the functions of a molecular biology lab on a small disposable chip.

Along with addressing the applied market, the deal, Ithaca, NY-based Rheonix said, will "significantly" shorten the time by which it can enter the clinical market it its sample-to-result molecular diagnostic instrument.

Financial and other terms were not disclosed.

On Monday Life Tech also announced a five-year food safety deal with the US Food and Drug Administration aimed at detecting E. coli and Salmonella.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.